U.S. markets open in 6 hours 4 minutes
  • S&P Futures

    4,391.75
    +12.00 (+0.27%)
     
  • Dow Futures

    34,834.00
    +113.00 (+0.33%)
     
  • Nasdaq Futures

    14,985.25
    +32.50 (+0.22%)
     
  • Russell 2000 Futures

    2,220.10
    +9.20 (+0.42%)
     
  • Crude Oil

    71.10
    -0.16 (-0.22%)
     
  • Gold

    1,807.80
    -10.30 (-0.57%)
     
  • Silver

    25.32
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1884
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.1740
    0.0000 (0.00%)
     
  • Vix

    19.46
    +1.22 (+6.69%)
     
  • GBP/USD

    1.3909
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.1040
    -0.2050 (-0.19%)
     
  • BTC-USD

    38,489.86
    -1,736.51 (-4.32%)
     
  • CMC Crypto 200

    934.71
    -26.18 (-2.72%)
     
  • FTSE 100

    7,086.76
    +5.04 (+0.07%)
     
  • Nikkei 225

    27,641.83
    -139.19 (-0.50%)
     

CTI BioPharma's Pacritinib Demonstrates Positive Safety Profile In Graft-Versus-Host-Disease Study

·1 min read

CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib, to prevent acute graft-versus-host disease (GVHD).

  • Pacritinib showed an encouraging safety profile and exhibited preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic cell transplantation.

  • The Phase 2 portion of the trial is designed to evaluate the therapeutic effect of pacritinib in combination with sirolimus and low-dose tacrolimus for GVHD prevention.

  • The Phase 1 portion of the trial evaluated the safety of pacritinib when administered with sirolimus, plus low-dose tacrolimus after allogeneic hematopoietic cell transplantation.

  • A 3+3 dose escalation design identified Pacritinib 100 mg twice a day as the minimum biologically active and well-tolerated dose for further study.

  • The new manuscript reports that dual JAK2/mTOR inhibition suppresses pathogenic Th1 and Th17 cells, enhances the potency of immunosuppressive regulatory T cells (Tregs) and maintains natural killer cells and CD8+ cytotoxic T lymphocytes required for graft-versus-leukemia.

  • Notably, PAC/SIR/TAC was observed to preserve donor cytomegalovirus (CMV) immunity, permit timely engraftment, and avoid cytopenias observed with nonselective JAK inhibitors.

  • Pacritinib is an oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development and inflammatory cytokine expression and immune responses. 

  • Price Action: CTIC shares trading 2.03% higher at $3.27 in market hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.